Clinical Trials Sponsored by Merck Sharp & Dohme LLC

Total 4143 results

Merck Sharp & Dohme LLC

Not yet recruiting

A Study of Sotatercept (MK-7962) in Healthy Females Administered as a Liquid Formulation in an Autoinjector Versus the Lyophilized Formulation (MK-7962-027)

Healthy
Merck Sharp & Dohme LLC

Not yet recruiting

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION) (LIGHTRAY EXT)

Pulmonary Arterial Hypertension

Colombia
Merck Sharp & Dohme LLC

Not yet recruiting

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBL) (MK-2140-011/waveLINE-011)

Lymphoma, Large B-Cell, Diffuse
Merck Sharp & Dohme LLC

Recruiting

A Study of the Effect of Multiple Doses of Diltiazem on the Plasma Levels of MK-6916 in Healthy Participants (MK-6916-005)

Healthy

United States
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)

Lung Neoplasm Malignant

United States, Poland
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)

Malignant Neoplasm

Israel
Merck Sharp & Dohme LLC

Recruiting

A Clinical Study to Evaluate Enlicitide (MK-0616) Formulations in Healthy Adult Participants (MK-0616-035)

Healthy

United States
Merck Sharp & Dohme LLC

Not yet recruiting

A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009)

Hepatic Impairment | Healthy Participants
Merck Sharp & Dohme LLC

Recruiting

A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)

Early Triple Negative Breast Cancer

United States, Taiwan
Merck Sharp & Dohme LLC

Recruiting

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

Advanced Solid Tumors | Malignant Neoplasm

Chile, Israel
Merck Sharp & Dohme LLC

Recruiting

A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)

Non-Small Cell Lung Cancer | Lung Cancer

Korea, Republic of, Poland, Romania, Spain, Guatemala, Japan, United States, China, Turkey, United Kingdom, Peru
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-2225 in Healthy Participants (MK-2225-003)

Systemic Sclerosis

United States
Merck Sharp & Dohme LLC

Recruiting

Safety and Immunogenicity of V540B in Healthy Adults (V540B-002).

Healthy

United States
Merck Sharp & Dohme LLC

Not yet recruiting

Single and Multiple Dose Study of MK-1708 in Healthy Japanese Participants (MK-1708-004)

Amyotrophic Lateral Sclerosis | Alzheimer Disease
Merck Sharp & Dohme LLC

Recruiting

A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)

Classical Hodgkin Lymphoma Recurrent | Classical Hodgkin Lymphoma Refractory | Primary Mediastinal Large B-cell Lymphoma Recurrent | Primary Mediastinal Large B-cell Lymphoma Refractory

Poland, United States, New Zealand, Spain, Chile, Korea, Republic of, United Kingdom, Australia, Mexico, Turkey, Germany
Merck Sharp & Dohme LLC

Recruiting

A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)

Non-alcoholic Fatty Liver Disease | NAFLD | Nonalcoholic Steatohepatitis | Metabolic Dysfunction-associated Steatotic Liver Disease | Metabolic Dysfunction-associated Steatohepatitis

Puerto Rico, United States, Australia, Israel, Japan, Spain, United Kingdom, France, Thailand, Colombia, Canada
Merck Sharp & Dohme LLC

Recruiting

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

Crohn's Disease

Canada, United States, Korea, Republic of, Greece, Italy, Japan, Chile, Israel, Switzerland, Austria, Croatia, China, Belgium, Ukraine, France, Netherlands, Portugal, United Kingdom, Germany, Sweden, Taiwan, Romania, Hungary, Australia, Singapor... and more
Merck Sharp & Dohme LLC

Recruiting

A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

Primary Myelofibrosis | Polycythemia Vera | Thrombocythemia, Essential | Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

Australia, Italy, New Zealand, United States, United Kingdom, Hong Kong
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004)

Non-small Cell Lung Cancer

Argentina, United States, Korea, Republic of, Ukraine, China, Chile, Japan, Brazil, Australia, Netherlands, Romania, Spain, France, Georgia, Bulgaria, Philippines, Austria, Canada, New Zealand, Italy, Greece, Mexico
Merck Sharp & Dohme LLC

Recruiting

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Breast Neoplasms

Poland, Israel, Canada, United States, Taiwan, Hong Kong, Korea, Republic of, Switzerland, Costa Rica, Malaysia, Argentina, United Kingdom, Australia, Puerto Rico, Chile, Colombia, Netherlands, Brazil, France, Greece, Hungary, Rom... and more
Merck Sharp & Dohme LLC

Recruiting

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (TroFuse-019)

Non Small Cell Lung Cancer

Poland, Chile, Germany, Belgium, United States, Israel, Taiwan, Korea, Republic of, Switzerland, Canada, Hong Kong, Portugal, Brazil, Greece, Australia, China, Argentina, Austria, France, Netherlands, Norway, Peru, Romania, Spain, Mexico, Turke... and more
Merck Sharp & Dohme LLC

Recruiting

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Non-small Cell Lung Cancer (NSCLC)

China, Poland, Canada, United States, Turkey, Taiwan, Korea, Republic of, Malaysia, Argentina, Spain, France, Colombia, Italy, Japan, Sweden, Mexico, Thailand, India, Vietnam
Merck Sharp & Dohme LLC

Recruiting

A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)

Squamous Cell Carcinoma

Japan
Merck Sharp & Dohme LLC

Recruiting

Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008) (MOONBEAM)

Pulmonary Arterial Hypertension

Germany, United States, Poland, Spain, Colombia, France, Turkey, Israel, Australia, United Kingdom, South Africa, Netherlands
Merck Sharp & Dohme LLC

Recruiting

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

Esophageal Squamous Cell Carcinoma

Japan, Korea, Republic of, Taiwan, China, Norway, Italy, Switzerland, Brazil, Germany, Singapore, Turkey, Thailand, Chile, United States
Merck Sharp & Dohme LLC

Not yet recruiting

Radiopaque Matrix MK-8591 Implant in Participants at Low-Risk for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591-043)

HIV | Human Immunodeficiency Virus
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001) (KANDLELIT-001)

Advanced Solid Tumors

China, United States, Australia, Canada, Chile, Israel, Japan, Korea, Republic of, Panama, Poland, Spain, Switzerland, Turkey, New Zealand, Taiwan, Denmark, Italy, Ukraine
Merck Sharp & Dohme LLC

Recruiting

Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)

Invasive Fungal Infection

Israel, United States, Belgium, Greece, Peru, Poland, Mexico, Russian Federation, Korea, Republic of, Ukraine
Merck Sharp & Dohme LLC

Completed

A Study of Belzutifan (MK-6482) in Participants With Renal Impairment (MK-6482-021)

End Stage Renal Disease | Renal Impairment

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)

Neoplasm Malignant

Israel, United States, Australia, Belgium, Chile, France, Korea, Republic of, Netherlands, New Zealand, Spain
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

Esophageal Squamous Cell Carcinoma (ESCC)

Japan, Italy, Brazil, Chile, France, Germany, Korea, Republic of, Norway, Singapore, Switzerland, Taiwan, Thailand, Turkey
Merck Sharp & Dohme LLC

Completed

Immunobridging Study of 9- Valent Human Papillomavirus (9vHPV) Vaccine (V503) in Chinese Females 9 to 45 Years of Age (V503-024)

Papillomavirus Infections

China
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003)

Malaria

Australia
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate Laser Speckle Contrast Imaging to Assess Changes in Chemical Agent-Induced Skin Blood Flow in Healthy Participants (MK-0000-420)

Healthy

Belgium
Merck Sharp & Dohme LLC

Completed

Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104)

Invasive Aspergillosis

Belgium, United States, Greece, Hungary, Israel, Italy, Korea, Republic of, Mexico, Peru, Russian Federation
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)

Papillomavirus Infections

United States, Belgium, Brazil, Colombia, Czechia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Mexico, Peru, Spain, Taiwan, Thailand
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension

Metastatic Hormone-Sensitive Prostate Cancer

China
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

Prostatic Neoplasms

United States, Argentina, Australia, Austria, Brazil, Canada, Chile, Colombia, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Netherlands, Russian Federation, Spain, Taiwan, United Kingdom, Bulgaria, Czechia, Hu... and more
Merck Sharp & Dohme LLC

Completed

Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)

Chemotherapy-induced Nausea and Vomiting

United States, Greece, Hungary, Lithuania, Netherlands, Peru, Poland, Russian Federation, United Kingdom
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Effect of Food on Nemtabrutinib (MK-1026) in Healthy Participants (MK-1026-016)

Healthy

United States
Merck Sharp & Dohme LLC

Completed

A Study of Efinopegdutide in Healthy Obese Participants (MK-6024-015)

Healthy

United States
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)

Hodgkin's Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL)

Canada, United States, Brazil, Czechia, France, Italy, Poland, Russian Federation, South Africa, Turkey, Ukraine
Merck Sharp & Dohme LLC

Active, not recruiting

Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866) (KEYNOTE-866)

Bladder Cancer

Canada, United States, Australia, Belgium, Denmark, France, Germany, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Mexico, Poland, Russian Federation, Spain, Sweden, Thailand, Turkey, Ukraine, United Kingdom
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)

Metastatic Urothelial Carcinoma | Urothelial Neoplasms

Australia, United States, Canada, Chile, France, Israel, Italy, Korea, Republic of, Netherlands, Spain, Taiwan, United Kingdom
Merck Sharp & Dohme LLC

Terminated

Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024) (Impower-024)

HIV Preexposure Prophylaxis

United States, Brazil, France, Japan, South Africa, Thailand, Peru
Merck Sharp & Dohme LLC

Completed

A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)

Hematological Malignancies

United States, Canada, Brazil, Chile, Denmark, France, Germany, Hungary, Israel, Italy, Poland, Russian Federation, Spain, Taiwan, Turkey, Ukraine
Merck Sharp & Dohme LLC

Completed

Activity Tracking Study in Healthy Volunteers (MK-0000-419)

Healthy

United States
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)

Advanced Non-Small Cell Lung Cancer

Poland, Russian Federation, United States, Australia, Canada, Hong Kong, Ireland, Italy, Japan, Korea, Republic of, Singapore, South Africa, Spain, Switzerland, Taiwan, United Kingdom
Merck Sharp & Dohme LLC

Completed

Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)

Stomach Neoplasms

China, Japan, Poland, Turkey, Brazil, United States, Argentina, Australia, Canada, Chile, Colombia, Costa Rica, Czechia, Denmark, France, Germany, Guatemala, Hong Kong, Hungary, Ireland, Israel, Italy, Korea, Republic of, Mexico, New Zealand and more
Merck Sharp & Dohme LLC

Completed

Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)

Merkel Cell Carcinoma

United States, Australia, Canada, France, Italy, New Zealand, Spain, Sweden

Clinical Trials Sponsored by Merck Sharp & Dohme LLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations